Table 2 Pathological and biological characteristics of elderly Korean women with breast cancer
Group | ||||
|---|---|---|---|---|
Variable | Total no. of analyzed patients (%) | Old-onset breast cancer (≥70) | Non old-onset breast cancer (40 ~ 69) | p value |
(N = 102,379) | (N = 6104) | (n = 96,275) | ||
Multiplicity | 77,724 (75.9) | <.0011 | ||
Single | 69,006 | 4177 (91.1) | 64,829 (88.6) | |
Two | 5922 | 292 (6.4) | 5630 (7.7) | |
More than 3 | 2796 | 117 (2.6) | 2679 (3.7) | |
Missing | 24,655 | 1518 | 23,137 | |
Histologic grade | 101,082 (98.7) | <.0011 | ||
Low, intermediate | 48,181 | 3057 (50.6) | 45,124 (47.5) | |
High | 52,901 | 2988 (49.4) | 49,913 (52.5) | |
Missing | 1297 | 59 | 1238 | |
Histopathology | 102,379(100.0) | <.0011 | ||
In situ | 10,402 | 453 (7.4) | 9949 (10.3) | |
IDC | 75,924 | 4415 (72.3) | 71,509 (74.3) | |
ILC | 2838 | 151 (2.5) | 2687 (2.8) | |
Mucinous carcinoma | 1962 | 250 (4.1) | 1712 (1.8) | |
Others | 11,253 | 835 (13.7) | 10,418 (10.8) | |
Presence of lymphovascular invasion | 67,118 (65.6) | .0061 | ||
Yes | 22,651 | 1288 (31.8) | 21,363 (33.9) | |
No | 44,467 | 2768 (68.2) | 41,699 (66.1) | |
Missing | 35,261 | 2048 | 33,213 | |
ER | 90,827 (88.7) | .1211 | ||
Positive | 61,811 | 3675 (69.0) | 58,136 (68.0) | |
Negative | 29,016 | 1650 (31.0) | 27,366 (32.0) | |
Missing | 11,552 | 779 | 10,773 | |
PR | 90,732 (88.6) | <.0011 | ||
Positive | 54,019 | 2964 (55.8) | 51,055 (59.8) | |
Negative | 36,713 | 2346 (44.2) | 34,367 (40.2) | |
Missing | 11,647 | 794 | 10,853 | |
HER2 | 76,508 (74.7) | <.0011 | ||
Positive | 18,945 | 892 (19.6) | 18,053 (25.1) | |
Negative | 57,563 | 3662 (80.4) | 53,901 (74.9) | |
Missing | 25,871 | 1550 | 24,321 | |
Ki-67 | 45,789 (44.7) | <.0011 | ||
< 14% | 22,213 | 1528 (51.9) | 20,685 (48.3) | |
≥ 14% | 23,576 | 1418 (48.1) | 22,158 (51.7) | |
Missing | 56,590 | 3158 | 53,432 | |
Subtype | 76,349 (74.6) | |||
HR+/HER2- (Luminal A) | 45,133 | 2841 (62.6) | 42,292 (58.9) | <.0011 |
HR+/HER2+ (Luminal B) | 9300 | 398 (8.8) | 8902 (12.4) | <.0011 |
HR−/HER2+ (HER2) | 9595 | 487 (10.7) | 9108 (12.7) | <.0011 |
HR−/HER2- (TNBC) | 12,321 | 813 (17.9) | 11,508 (16.0) | <.0011 |
Missing | 26,030 | 1565 | 24,465 | |
pT | 98,583(96.3) | <.0011 | ||
T0, Tis, T1 | 60,484 | 3287 (56.1) | 57,197 (61.7) | |
T2, T3, T4 | 38,059 | 2572 (43.9) | 35,487 (38.3) | |
Tx | 40 | 0 | 40 | |
Missing | 0 | 0 | 0 | |
pN | 98,583 (96.3) | .0641 | ||
N0, N1 | 87,344 | 5142 (87.9) | 82,202 (88.7) | |
N2, N3 | 11,175 | 707 (12.1) | 10,468 (11.3) | |
Nx | 45 | 6 | 39 | |
Missing | 19 | 4 | 15 | |
pM | 98,583 (96.3) | .0081 | ||
M0 | 97,511 | 5775 (98.6) | 91,736 (98.9) | |
M1 | 1072 | 84 (1.4) | 988 (1.1) | |
Missing | 0 | 0 | 0 | |
p Stage | 98,583 (96.3) | <.0011 | ||
0, I | 48,210 | 2667 (45.5) | 45,543 (49.1) | |
II, III, IV | 50,373 | 3192 (54.5) | 47,181 (50.9) | |
Missing | 0 | 0 | 0 | |
Chemotherapy | 85,570 (83.6) | <.0011 | ||
Yes | 56,714 | 1668 (34.4) | 55,046 (68.2) | |
No | 28,856 | 3176 (65.6) | 25,680 (31.8) | |
Missing | 16,809 | 1260 | 15,549 | |
Chemotherapy | 56,714 (55.4) | <.0011 | ||
Neoadjuvant | 2767 | 81 (5.1) | 2686 (5.2) | |
Adjuvant | 49,519 | 1471 (91.8) | 48,048 (92.2) | |
Neoadjuvant and adjuvant | 1032 | 23 (1.4) | 1009 (1.9) | |
Palliative | 425 | 28 (1.7) | 397 (0.8) | |
Missing | 2971 | 65 | 2906 | |
Radiotherapy | 82,800 (80.9) | <.0011 | ||
Yes | 51,950 | 1796 (37.8) | 50,154 (64.3) | |
No | 30,850 | 2961 (62.2) | 27,889 (35.7) | |
Missing | 19,579 | 1347 | 18,232 | |
Radiotherapy | 51,950 (50.7) | .1761 | ||
Adjuvant | 46,400 | 1642 (98.4) | 44,758 (98.8) | |
Palliative | 590 | 27 (1.6) | 563 (1.2) | |
Missing | 4960 | 127 | 4833 | |
Hormonal therapy | 80,877 (79.0) | .9371 | ||
Yes | 57,041 | 3416 (70.6) | 53,625 (70.5) | |
No | 23,836 | 1424 (29.4) | 22,412 (29.5) | |
Missing | 21,502 | 1264 | 20,238 | |